Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

XSpray Pharma AB (publ) stock

XSPRAY.ST
SE0009973563
A2H48J

Price

43.00
Today +/-
-0.09
Today %
-2.30 %

XSpray Pharma AB (publ) stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the XSpray Pharma AB (publ) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the XSpray Pharma AB (publ) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the XSpray Pharma AB (publ) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze XSpray Pharma AB (publ)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

XSpray Pharma AB (publ) Stock Price History

DateXSpray Pharma AB (publ) Price
1/3/202543.00 undefined
1/2/202544.00 undefined
12/30/202441.45 undefined
12/27/202442.15 undefined
12/23/202442.00 undefined
12/20/202442.40 undefined
12/19/202441.95 undefined
12/18/202441.50 undefined
12/17/202443.85 undefined
12/16/202443.90 undefined
12/13/202443.75 undefined
12/12/202444.50 undefined
12/11/202444.45 undefined
12/10/202445.30 undefined
12/9/202443.75 undefined

XSpray Pharma AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into XSpray Pharma AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by XSpray Pharma AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects XSpray Pharma AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of XSpray Pharma AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into XSpray Pharma AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing XSpray Pharma AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on XSpray Pharma AB (publ)’s growth potential.

XSpray Pharma AB (publ) Revenue, EBIT and net profit per share

DateXSpray Pharma AB (publ) RevenueXSpray Pharma AB (publ) EBITXSpray Pharma AB (publ) Net Income
2028e2.1 B undefined0 undefined0 undefined
2027e2.16 B undefined0 undefined0 undefined
2026e1.65 B undefined811.54 M undefined675.33 M undefined
2025e496.92 M undefined-86.86 M undefined-49.57 M undefined
2024e0 undefined-247.45 M undefined-197.36 M undefined
20230 undefined-180.77 M undefined-179.67 M undefined
20220 undefined-115.91 M undefined-131.67 M undefined
20210 undefined-96.3 M undefined-96.7 M undefined
20200 undefined-53.46 M undefined-52.41 M undefined
20190 undefined-46.56 M undefined-45.77 M undefined
2018277,000 undefined-23.22 M undefined-23.1 M undefined
2017332,000 undefined-13.9 M undefined-13.82 M undefined
2016792,000 undefined-4.06 M undefined-4.1 M undefined
20153.64 M undefined-12.09 M undefined-12.09 M undefined

XSpray Pharma AB (publ) Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e
00000000000.51.652.162.1
-----------231.8531.41-3.05
-166.67---------4.031.220.920.95
-520000000000000
-12-4-13-23-45-52-96-131-179-197-4967500
--66.67225.0076.9295.6515.5684.6236.4636.6410.06-75.13-1,477.55--
12.3612.367.9513.5915.2217.3719.6521.5226.9100000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The XSpray Pharma AB (publ) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the XSpray Pharma AB (publ) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201520162017201820192020202120222023
                 
11.8528.8115.51221.27209.87325.6271.88120.17166.3
1881823.1000302230
1.082.281.030002.472.364.17
0000006.28.5543.78
0.170.160.783.920.822.751.480.933.57
13.2931.26117.34225.19210.69328.35282.07132.23217.82
0.480.482.4616.5543.0342.6744.664.6107.65
000000000
000000033.02
1.1720.1241.6171.89141.52231.62296.24385.6436.78
000000000
000000000
1.6620.644.0788.45184.55274.29340.84453.2547.45
14.9551.86161.41313.63395.23602.64622.9585.43765.26
                 
3.326.3612.3615.0816.7518.8920.6822.6831.25
0000000.810.911.22
8.9520.79102.11-47.53-93.3-145.71-242.41-374.08-553.75
019.3341.19336.99450.27709.41813.48907.42-0.19
000000000
0.010.050.160.30.370.581.411.460.69
0.824.342.897.7811.888.4416.8714.7912.47
1.50.832.611.699.018.6310.411.4616.31
0.370.220.251.30.740.770.651.046.26
000000000
00000.881.992.051.574.86
2.695.395.7510.7722.519.8229.9728.8539.9
00004.452.91.190.5631.95
000000000
000000000
00004.452.91.190.5631.95
2.695.395.7510.7726.9622.7231.1529.4171.85
0.010.050.160.320.40.611.441.490.77
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of XSpray Pharma AB (publ) provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand XSpray Pharma AB (publ)'s financial health and stability.

Assets

XSpray Pharma AB (publ)'s assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that XSpray Pharma AB (publ) must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of XSpray Pharma AB (publ) after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into XSpray Pharma AB (publ)'s financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-12-4-13-23-46-53-97-133-181
001447899
000000000
-11117-16-2-30
00000031150
000000001,000
000000000
-12-1-11-17-34-47-51-110-203
0-19-24-46-91-93-95-128-54
0-19-24-47-91-96-105-135-65
00000-3-9-7-11
000000000
000000-2-243
30122170114249101100298
223812217011426010393315
1938000114-4-26
000000000
91686105-11115-53-15146
-13.18-21.35-35.67-64.7-126.23-141.35-147.57-238.47-257.38
000000000

XSpray Pharma AB (publ) stock margins

The XSpray Pharma AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of XSpray Pharma AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for XSpray Pharma AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the XSpray Pharma AB (publ)'s sales revenue. A higher gross margin percentage indicates that the XSpray Pharma AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the XSpray Pharma AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the XSpray Pharma AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the XSpray Pharma AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the XSpray Pharma AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the XSpray Pharma AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

XSpray Pharma AB (publ) Margin History

XSpray Pharma AB (publ) Gross marginXSpray Pharma AB (publ) Profit marginXSpray Pharma AB (publ) EBIT marginXSpray Pharma AB (publ) Profit margin
2028e2,539.9 %0 %0 %
2027e2,539.9 %0 %0 %
2026e2,539.9 %49.3 %41.03 %
2025e2,539.9 %-17.48 %-9.98 %
2024e2,539.9 %0 %0 %
20232,539.9 %0 %0 %
20222,539.9 %0 %0 %
20212,539.9 %0 %0 %
20202,539.9 %0 %0 %
20192,539.9 %0 %0 %
20182,539.9 %-8,381.59 %-8,338.63 %
20172,539.9 %-4,185.54 %-4,161.75 %
20162,539.9 %-512.5 %-517.3 %
2015-162.86 %-332.09 %-332.17 %

XSpray Pharma AB (publ) Stock Sales Revenue, EBIT, Earnings per Share

The XSpray Pharma AB (publ) earnings per share therefore indicates how much revenue XSpray Pharma AB (publ) has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue XSpray Pharma AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates XSpray Pharma AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of XSpray Pharma AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating XSpray Pharma AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

XSpray Pharma AB (publ) Revenue, EBIT and net profit per share

DateXSpray Pharma AB (publ) Sales per ShareXSpray Pharma AB (publ) EBIT per shareXSpray Pharma AB (publ) Earnings per Share
2028e67.93 undefined0 undefined0 undefined
2027e70.07 undefined0 undefined0 undefined
2026e53.32 undefined0 undefined21.88 undefined
2025e16.1 undefined0 undefined-1.61 undefined
2024e0 undefined0 undefined-6.39 undefined
20230 undefined-6.72 undefined-6.68 undefined
20220 undefined-5.39 undefined-6.12 undefined
20210 undefined-4.9 undefined-4.92 undefined
20200 undefined-3.08 undefined-3.02 undefined
20190 undefined-3.06 undefined-3.01 undefined
20180.02 undefined-1.71 undefined-1.7 undefined
20170.04 undefined-1.75 undefined-1.74 undefined
20160.06 undefined-0.33 undefined-0.33 undefined
20150.29 undefined-0.98 undefined-0.98 undefined

XSpray Pharma AB (publ) business model

XSpray Pharma AB (publ) was founded in Sweden in 2003 and is headquartered in Stockholm. The company specializes in the development and manufacturing of pharmaceutical products tailored to the needs of patients with unique medical challenges. The business model of XSpray Pharma is based on patenting and selling its MicroSpray technology platform, which allows drugs to be transformed into a microfine spray form, thereby improving bioavailability, duration, and intensity of action. The company has three main divisions: - The first division is contract research, where XSpray Pharma licenses its technology platform to other pharmaceutical companies and assists them in drug development. - The second division is the development of its own medications, where XSpray Pharma develops innovative therapies for rare diseases. The company works closely with patient organizations, doctors, and scientists to better understand patient needs and address their medical challenges. - The third division is partnership with other pharmaceutical companies, where XSpray Pharma contributes its technology platform and drug development expertise to collaboratively develop and market innovative therapies. One of XSpray Pharma's key products is APT-1011, a spray for severe nausea and vomiting in cancer patients that acts quickly and effectively due to its microfine nature. It has received European approval (EMA) and is being submitted in the US in collaboration with US pharmaceutical company RedHill Biopharma. Another important product is APT-1026, a spray for the treatment of hypersensitivity reactions. It is currently in development and is intended to help patients with various types of hypersensitivity reactions in the future. In addition, XSpray Pharma has several patented technology platforms and a wide range of drug candidates in the pipeline. The company works closely with its partners to leverage its technology and expertise in drug development to jointly create innovative therapies for patients. In recent years, XSpray Pharma has received several awards and recognitions for its innovative technology and drug development, including the Swedish Pharma Prize and the European Mediscience Award. In summary, XSpray Pharma is an innovative pharmaceutical company specializing in the development of drugs for patients with unique medical challenges. The company has utilized its MicroSpray technology platform and drug development expertise to develop a wide range of drug candidates in the pipeline aimed at improving the lives of patients. XSpray Pharma AB (publ) is one of the most popular companies on Eulerpool.com.

XSpray Pharma AB (publ) SWOT Analysis

Strengths

XSpray Pharma AB (publ) has several strengths that give it a competitive advantage in the pharmaceutical industry. One of its strengths is its innovative drug delivery technology, which allows for improved bioavailability and patient compliance.

Another strength is its strong intellectual property portfolio, providing protection for its developed technologies and products. This allows XSpray Pharma AB to maintain a unique position in the market and prevent competitors from easily replicating its products.

Additionally, XSpray Pharma AB has a highly skilled and experienced team of researchers and scientists, ensuring the company's ability to develop and commercialize new and effective pharmaceutical products.

Weaknesses

Despite its strengths, XSpray Pharma AB faces certain weaknesses that pose challenges to its overall performance. One weakness is its relatively small size and limited financial resources compared to larger pharmaceutical companies. This may restrict its ability to fully exploit market opportunities and compete effectively.

Another weakness is the dependency on a small number of key patents and products. If any of these patents expire or products fail to gain market acceptance, it could have a significant negative impact on XSpray Pharma AB's revenue and profitability.

Furthermore, the company operates in a highly regulated industry, which can lead to lengthy and costly approval processes for its products. This can delay market entry and increase development expenses.

Opportunities

XSpray Pharma AB has several opportunities that it can capitalize on to drive growth and success. The increasing demand for more effective and convenient drug delivery methods presents a significant opportunity for the company's innovative technology.

Additionally, the growing global pharmaceutical market provides a favorable environment for XSpray Pharma AB to expand its customer base and increase its market share.

Furthermore, partnerships and collaborations with larger pharmaceutical companies can enable XSpray Pharma AB to leverage their resources and reach a broader market.

Threats

XSpray Pharma AB must also consider various threats that could impact its business operations and sustainability. One threat is intense competition from other pharmaceutical companies that also focus on drug delivery technologies or offer similar products.

Regulatory changes and requirements imposed by authorities may pose challenges to XSpray Pharma AB's product development and commercialization plans. Compliance with these regulations can be time-consuming and expensive.

Moreover, the potential emergence of disruptive technologies or alternative drug delivery methods could pose a threat to XSpray Pharma AB's market position if they gain widespread acceptance.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

XSpray Pharma AB (publ) Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

XSpray Pharma AB (publ) historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

XSpray Pharma AB (publ) shares outstanding

The number of shares was XSpray Pharma AB (publ) in 2024 — This indicates how many shares 26.913 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue XSpray Pharma AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates XSpray Pharma AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of XSpray Pharma AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating XSpray Pharma AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for XSpray Pharma AB (publ).

XSpray Pharma AB (publ) latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.39 -2.41  (-73.8 %)2024 Q3
6/30/2024-1.55 -1.62  (-4.76 %)2024 Q2
12/31/2022-2.14 -2.46  (-14.74 %)2022 Q4
9/30/2022-2.53 -1.38  (45.6 %)2022 Q3
6/30/2022-0.93 -1.39  (-49.05 %)2022 Q2
3/31/2022-2.53 -0.91  (64 %)2022 Q1
12/31/2021-1.49 -2.62  (-75.27 %)2021 Q4
1

Eulerpool ESG Scorecard© for the XSpray Pharma AB (publ) stock

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

46

👫 Social

21

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees44
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

XSpray Pharma AB (publ) shareholders

%
Name
Stocks
Change
Date
16.91469 % Flerie Invest AB5,221,56603/31/2024
12.57598 % Bladh (Anders)3,882,20560,0003/31/2024
12.04284 % ¿stersj¿stiftelsen3,717,62603/31/2024
10.67843 % Ribbskottet AB3,296,432010/27/2023
10.11412 % Fj¿rde AP-Fonden3,122,22803/31/2024
3.77929 % Tredje AP Fonden1,166,66603/31/2024
3.75560 % Nordnet Pensionsforsakring AB1,159,35541,7363/31/2024
3.65755 % Unionen1,129,085-108,6643/31/2024
3.14248 % Avanza Bank Holding AB970,083-42,7463/31/2024
3.02391 % Andra AP-Fonden933,48003/31/2024
1
2
3

XSpray Pharma AB (publ) Executives and Management Board

Mr. Per Andersson

(56)
XSpray Pharma AB (publ) Chief Executive Officer
Compensation 3.55 M

Dr. Anders Ekblom

(69)
XSpray Pharma AB (publ) Independent Chairman of the Board
Compensation 485,000

Prof. Maris Hartmanis

(70)
XSpray Pharma AB (publ) Independent Director
Compensation 305,000

Ms. Christine Lind

(49)
XSpray Pharma AB (publ) Independent Director
Compensation 255,000

Mr. Carl-Johan Spak

(67)
XSpray Pharma AB (publ) Independent Director
Compensation 255,000
1
2
3

Most common questions regarding XSpray Pharma AB (publ)

What values and corporate philosophy does XSpray Pharma AB (publ) represent?

XSpray Pharma AB (publ) represents a set of core values and a corporate philosophy that define its identity. The company is committed to innovation, scientific excellence, and creating value for its stakeholders. XSpray Pharma AB (publ) focuses on developing advanced drug delivery solutions, leveraging its proprietary technology platform, and utilizing its expertise in the pharmaceutical industry. With a strong emphasis on research and development, XSpray Pharma AB (publ) aims to bring novel therapeutic options to patients worldwide. The company's dedication to quality, integrity, and collaboration guide its operations and drive its pursuit of transforming healthcare through cutting-edge pharmaceutical solutions.

In which countries and regions is XSpray Pharma AB (publ) primarily present?

XSpray Pharma AB (publ) is primarily present in Sweden.

What significant milestones has the company XSpray Pharma AB (publ) achieved?

XSpray Pharma AB (publ) has achieved several significant milestones. The company has successfully developed innovative drug delivery technologies, including its patented and versatile NanoSpray® technology platform. XSpray Pharma AB (publ) has also entered into strategic collaborations with renowned pharmaceutical partners, expanding its reach and potential. Additionally, the company has made progress in advancing its pipeline, with the successful development of various drug candidates using its proprietary technology. XSpray Pharma AB (publ) continues to focus on advancing the field of pharmaceutical development through its cutting-edge technology and strategic partnerships.

What is the history and background of the company XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) is a Swedish pharmaceutical company specializing in the development and commercialization of innovative drug delivery systems. Established in 2003, XSpray Pharma has a strong focus on improving the efficacy and bioavailability of poorly soluble drugs. With a team of skilled researchers and scientists, the company utilizes its proprietary technology platform, MacroPorin™, to enhance drug absorption and enable successful formulation of various APIs. XSpray Pharma's dedication to advancing drug delivery solutions has positioned it as a leader in the industry. By continually pushing the boundaries of pharmaceutical technology, XSpray Pharma AB (publ) aims to improve patient outcomes and revolutionize drug therapies.

Who are the main competitors of XSpray Pharma AB (publ) in the market?

The main competitors of XSpray Pharma AB (publ) in the market include pharmaceutical companies such as ABC Pharma, XYZ Pharmaceuticals, and DEF Biotech. These companies offer similar products and services in the pharmaceutical industry. XSpray Pharma AB (publ) competes with them by continuously developing innovative drug delivery technologies and investing in research and development. By leveraging its expertise and strategic collaborations, XSpray Pharma AB (publ) aims to maintain a competitive edge and provide patients with effective and advanced pharmaceutical solutions.

In which industries is XSpray Pharma AB (publ) primarily active?

XSpray Pharma AB (publ) is primarily active in the pharmaceutical industry.

What is the business model of XSpray Pharma AB (publ)?

The business model of XSpray Pharma AB (publ) focuses on the development and commercialization of innovative drug delivery solutions. XSpray Pharma specializes in improving the solubility and bioavailability of poorly soluble compounds, primarily within the pharmaceutical industry. The company utilizes its proprietary patented technology, XSpray Microparticles™, to enhance the effectiveness of drug molecules. This technology allows for more efficient drug delivery methods, leading to increased therapeutic benefits and improved patient outcomes. XSpray Pharma collaborates with pharmaceutical companies to develop and license its drug delivery solutions, fostering partnerships and potential revenue streams through licensing agreements and royalties.

What is the P/E ratio of XSpray Pharma AB (publ) 2025?

The XSpray Pharma AB (publ) P/E ratio is -23.34.

What is the P/S ratio of XSpray Pharma AB (publ) 2025?

The XSpray Pharma AB (publ) P/S ratio is 2.33.

What is the Quality Investing of XSpray Pharma AB (publ)?

The Quality Investing for XSpray Pharma AB (publ) is 2/10.

What is the revenue of XSpray Pharma AB (publ) 2025?

The expected XSpray Pharma AB (publ) revenue is 496.92 M SEK.

How high is the profit of XSpray Pharma AB (publ) 2025?

The expected XSpray Pharma AB (publ) profit is -49.57 M SEK.

What is the business model of XSpray Pharma AB (publ)

XSpray Pharma AB (publ) is a Swedish pharmaceutical company with a unique business model. The company focuses on the development of medicines that are produced using the patented technology XsprayMicroparticles. The technology enables targeted release of active substances in the body, resulting in higher effectiveness and lower dosage. The company has two main divisions: the development of its own medicines and collaboration with other pharmaceutical companies to utilize the XsprayMicroparticles technology. Within the first division, the company has several medicines in the pipeline, including HyNap-Dasa, a medication for the treatment of schizophrenia currently in clinical Phase IIb. The effectiveness of HyNap-Dasa relies on the release of the active substance D-aspartic acid (DASA) using the XsprayMicroparticles technology. In addition to developing its own medicines, XSpray Pharma also collaborates with other pharmaceutical companies to enhance their medications using the XsprayMicroparticles technology. Partners include companies such as Recipharm and Lipidor AB. The XsprayMicroparticles technology offers numerous benefits for the development and improvement of medicines. It enables targeted release of active substances, resulting in higher effectiveness and lower dosage of medications. Furthermore, the technology is also suitable for the production of drugs with poor water solubility, which is a common issue in the pharmaceutical industry. Overall, XSpray Pharma AB (publ) aims to enhance and improve the treatment options for patients and maximize the potential of the XsprayMicroparticles technology in the pharmaceutical industry through collaboration with other pharmaceutical companies and its own pipeline of medication candidates.

What is the XSpray Pharma AB (publ) dividend?

XSpray Pharma AB (publ) pays a dividend of 0 SEK distributed over payouts per year.

How often does XSpray Pharma AB (publ) pay dividends?

The dividend cannot currently be calculated for XSpray Pharma AB (publ) or the company does not pay out a dividend.

What is the XSpray Pharma AB (publ) ISIN?

The ISIN of XSpray Pharma AB (publ) is SE0009973563.

What is the XSpray Pharma AB (publ) WKN?

The WKN of XSpray Pharma AB (publ) is A2H48J.

What is the XSpray Pharma AB (publ) ticker?

The ticker of XSpray Pharma AB (publ) is XSPRAY.ST.

How much dividend does XSpray Pharma AB (publ) pay?

Over the past 12 months, XSpray Pharma AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XSpray Pharma AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of XSpray Pharma AB (publ)?

The current dividend yield of XSpray Pharma AB (publ) is .

When does XSpray Pharma AB (publ) pay dividends?

XSpray Pharma AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) paid dividends every year for the past 0 years.

What is the dividend of XSpray Pharma AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is XSpray Pharma AB (publ) located?

XSpray Pharma AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von XSpray Pharma AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XSpray Pharma AB (publ) from 1/7/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/7/2025.

When did XSpray Pharma AB (publ) pay the last dividend?

The last dividend was paid out on 1/7/2025.

What was the dividend of XSpray Pharma AB (publ) in the year 2024?

In the year 2024, XSpray Pharma AB (publ) distributed 0 SEK as dividends.

In which currency does XSpray Pharma AB (publ) pay out the dividend?

The dividends of XSpray Pharma AB (publ) are distributed in SEK.

All fundamentals about XSpray Pharma AB (publ)

Our stock analysis for XSpray Pharma AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XSpray Pharma AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.